Lexaria Launches 18-Arm GLP-1 Animal Study Testing Amycretin and Retatrutide
Lexaria has engaged a contract research organization to execute its 2026 Animal Study #2 (GLP-1-A26-2), testing DehydraTECH-enhanced formulations with amycretin and retatrutide across 18 study arms. Formulation manufacturing is underway, dosing starts within 30 days, and the study will compare pill versus capsule absorption to improve pharmacokinetics and reduce gastrointestinal side effects.
1. Study Engagement and Scope
Lexaria has signed contracts with a CRO to execute its Animal Study #2 (GLP-1-A26-2), evaluating DehydraTECH formulations across 18 distinct study arms. The study aims to explore new intellectual property claims while demonstrating enhanced bio-absorption and tolerability of next-generation GLP-1 drugs.
2. Study Design and Objectives
The protocol involves blood sampling at multiple timepoints through a 24-hour post-dosing period to quantify pharmacokinetic performance of each formulation. Primary objectives include comparing pill and capsule delivery formats and assessing reductions in nausea, diarrhea and vomiting commonly associated with amycretin and retatrutide.
3. Drug Candidates and Formulations
Lexaria will test amycretin (owned by Novo Nordisk) and retatrutide (owned by Eli Lilly) using its patented DehydraTECH composition and processing platform. Formulations will explore alternative absorption enhancers such as sodium caprate versus salcaprozate sodium (SNAC) used in existing oral GLP-1 therapies.
4. Study Timeline and Funding
Formulation manufacturing is underway and dosing is expected to begin within 30 days, with the study fully funded from existing corporate resources. Lexaria will issue stakeholder updates once the dosing phase commences.